TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP

TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP Nice have today published the following decision: Caplacizumab with plasma exchange and immunosuppression is recommended, within its marketing authorisation, as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP) in adults, and in young people…

Sanofi Genzyme Study

TTP Network would like to signpost members to a Sanofi Genzyme study which aims to help better understand what life is like after being diagnosed with TTP. We are looking for people with acquired TTP (aTTP) who have experienced an episode in the last 12 months, and for family members or friends of someone with…

IQVIA Patient Study

TTPNetwork has been approached by a research company called IQVIA. IQVIA, a global healthcare research firm, is running a research study to explore the experience of patients receiving infusions as long-term treatment for a condition or disease, or on a continuing basis to prevent a condition or disease from occurring, either at home or in…